Judd Moul

Overview:

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Positions:

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine

Surgery, Urology
School of Medicine

Professor of Surgery

Surgery, Urology
School of Medicine

Chief of the Division of Urology in the Department of Surgery

Surgery, Urology
School of Medicine

Professor in Anesthesiology

Anesthesiology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S. 1979

Pennsylvania State University

M.D. 1982

Thomas Jefferson University

Residency, Surgery

Walter Reed Army Medical Center

Residency, Urology

Walter Reed Army Medical Center

Fellowship, Urologic Oncology

Duke University

Grants:

Phase III Randomized Efficacy and Safety Study

Awarded By
Medivation, Inc.
Role
Principal Investigator
Start Date
End Date

A Prospective Observational Cohort Study of Patients with Castration Resistant Prostate Cancer

Awarded By
Astellas Pharma Global Development, Inc
Role
Principal Investigator
Start Date
End Date

Exercise Training, Erectile Dysfunction, and Prostate Cancer

Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

IPA - Jens Dannull

Awarded By
Veterans Administration Medical Center
Role
Principal Investigator
Start Date
End Date

IPA Agreement - Jens Dannull

Awarded By
Veterans Administration Medical Center
Role
Principal Investigator
Start Date
End Date

Publications:

Editorial Comment.

Authors
Scales, CD
MLA Citation
Scales, Charles D. “Editorial Comment.J Urol, vol. 195, no. 5, May 2016, p. 1491. Pubmed, doi:10.1016/j.juro.2015.11.085.
URI
https://scholars.duke.edu/individual/pub789577
PMID
26829560
Source
pubmed
Published In
The Journal of Urology
Volume
195
Published Date
Start Page
1491
DOI
10.1016/j.juro.2015.11.085

Better than expected natural history for men with nonmetastatic prostate cancer and rising PSA. Comment

Authors
MLA Citation
Moul, J. W. “Better than expected natural history for men with nonmetastatic prostate cancer and rising PSA. Comment.” Oncology Report, no. FALL, Sept. 2005, pp. 57–58.
URI
https://scholars.duke.edu/individual/pub789559
Source
scopus
Published In
Oncology Report
Published Date
Start Page
57
End Page
58

Is MRI fusion Bx the new gold standard for diagnosing PCA?

Authors
Nash, K; Strope, S; Eisenberg, R; Moul, J
MLA Citation
Nash, K., et al. “Is MRI fusion Bx the new gold standard for diagnosing PCA?Urology Times, vol. 48, no. 4, Apr. 2020.
URI
https://scholars.duke.edu/individual/pub1469274
Source
scopus
Published In
Urology Times
Volume
48
Published Date

Chemotherapy, bisphosphonates, now recommended for prostate cancer. Comment

Authors
MLA Citation
Moul, J. W. “Chemotherapy, bisphosphonates, now recommended for prostate cancer. Comment.” Oncology Report, no. FALL, Sept. 2005, pp. 53–54.
URI
https://scholars.duke.edu/individual/pub789561
Source
scopus
Published In
Oncology Report
Published Date
Start Page
53
End Page
54

Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.

BACKGROUND: The purpose of the study was to determine whether a difference is noted in the rate of prostate specific antigen (PSA) elevation after radical prostatectomy or radiation therapy for localized prostate cancer. METHODS: PSA doubling times were calculated by linear regression analysis in 50 patients who had been treated by radical prostatectomy and who had three or more increasing PSA levels and in 55 patients who had been treated with radiation therapy and who had three or more increasing PSA levels. RESULTS: No significant difference was noted in the mean PSA doubling times in the two patient groups when stratified by the site of tumor recurrence or by pretreatment tumor stage, tumor grade, or acid phosphatase level. CONCLUSIONS: Because the PSA doubling time probably parallels the tumor growth rate, these data suggest that the malignant potentials of recurrent tumor after radical prostatectomy and after radiation therapy are equivalent.
Authors
Fowler, JE; Pandey, P; Braswell, NT; Seaver, L
MLA Citation
URI
https://scholars.duke.edu/individual/pub753363
PMID
7519363
Source
pubmed
Published In
Surgery
Volume
116
Published Date
Start Page
302
End Page
305